Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 0.0× sales vs its 2.4× historical median P/S.
Fair value ≈ $8.98 · price $0.00 today
Undervalued · 100% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ENTX With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For >>
https://www.benzinga.com/content/60014792/positive-fda-feedback-phase-3-entera-bio-just-got-answer-market-was-waiting $LLY $NVOS $SEPN
$ENTX Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
https://www.globenewswire.com/news-release/2026/06/22/3315282/0/en/entera-bio-receives-positive-fda-feedback-on-12-month-registrational-phase-3-study-for-eb613-the-first-oral-anabolic-tablet-in-development-for-postmenopausal-women-with-osteoporosi.html $LLY $SEPN $NVOS
#NOVONORDISK
✅ Alleged major cybersecurity breach reported at Novo Nordisk
✅ Hackers claim to have stolen nearly 1TB of sensitive company data
✅ Cybercriminal group alleges the breach occurred after a $25 million ransom demand was rejected
✅ The stolen data is reportedly being threatened for public release
✅ Incident raises concerns over data security, operational risks, and potential regulatory implications
🚨 Investors will closely monitor the company's response and any impact on business operations.
$NVOS
I'm back, and fully recovered, thanks to massive profits from $SMMT and $NEOV, countered the clusterfuck that was $NVOS and their scumbag CEO. I have a banger, $KARX Legit fundamentals, already moving up, volume is picking up. Should be $1.50-$2.00 on actual fundamentals when their numbers come out in the next week or so. Get it now or don't come crying to me that you didn't.
Novo Nordisk
✅ Sets aggressive pricing strategy in India
✅ Starting dose of Ozempic & Wegovy priced at just ₹202/day
✅ Major step toward expanding obesity & diabetes treatment access
✅ Signals strong intent to capture India’s fast-growing GLP-1 market
✅ Could disrupt pricing dynamics in the domestic pharma space
$NVOS
$VKTX with $NVOS trying to find something better, im surprised Viking is getting bypassed by all these BP for a partnership or BO. Novo just partnered with Vivtex with up to 2bil to find and scale obesity & diabetes. Unless Viking is asking foe too much, waiting on that positive PH3 will be the only thing to moon the stock.
